CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +7,998 | $8.44 | $68K | 7,998 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +5,000 | $17.88 | $89K | 12,998 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +8,332 | $21.77 | $181K | 21,330 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +12,500 | $22.07 | $276K | 33,830 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −33,830 | $81.48 | $2.8M | 0 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,998 | 3,998 | ||
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 71,184 | ||
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,332 | 54,174 | ||
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,500 | 106,250 | ||
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Option exercise 10b5-1 | +122,918 | $6.70 | $824K | 122,918 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −43,505 | $80.69 | $3.5M | 79,413 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −65,517 | $81.74 | $5.4M | 13,896 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −12,796 | $82.60 | $1.1M | 1,100 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −200 | $83.38 | $17K | 900 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −900 | $85.53 | $77K | 0 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Option exercise · Stock Option (Right to Buy) 10b5-1 | −122,918 | 59,741 | ||
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +16,182 | $17.88 | $289K | 16,182 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +17,500 | $22.07 | $386K | 33,682 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +10,000 | $21.77 | $218K | 43,682 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −15,852 | $80.71 | $1.3M | 27,830 |
Page 8 of 24 · 470 trades